Stockscreener 앱 받기
8.70
3.33%
0.28
전일 마감가:
$8.42
열려 있는:
$8.55
하루 거래량:
3.22M
Relative Volume:
0.72
시가총액:
$1.41B
수익:
$1.08B
순이익/손실:
$422.82M
주가수익비율:
3.8158
EPS:
2.28
순현금흐름:
$-637.33M
1주 성능:
+5.45%
1개월 성능:
+0.35%
6개월 성능:
-1.69%
1년 성능:
+6.36%
1일 변동 폭
$8.4825
$8.91
1주일 범위
$8.02
$9.276
52주 변동 폭
$5.01
$10.64
노바백스 Stock (NVAX) Company Profile
명칭
Novavax Inc
전화
240-268-2000
주소
700 QUINCE ORCHARD ROAD, GAITHERSBURG, MD
Compare NVAX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
8.70 | 1.37B | 1.08B | 422.82M | -637.33M | 2.28 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
노바백스 Stock (NVAX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-08-28 | 재개 | H.C. Wainwright | Buy |
| 2025-08-20 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2025-06-17 | 개시 | Citigroup | Sell |
| 2025-02-28 | 개시 | BTIG Research | Buy |
| 2024-07-30 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2024-05-10 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2024-05-10 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2023-08-09 | 업그레이드 | B. Riley Securities | Neutral → Buy |
| 2023-04-20 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-03-01 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2023-01-09 | 재확인 | B. Riley Securities | Buy |
| 2022-12-30 | 재확인 | H.C. Wainwright | Buy |
| 2022-12-02 | 개시 | Jefferies | Hold |
| 2022-09-22 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-05-20 | 개시 | BofA Securities | Underperform |
| 2022-02-23 | 재확인 | B. Riley Securities | Buy |
| 2022-02-22 | 재개 | Jefferies | Buy |
| 2022-01-21 | 개시 | Cowen | Outperform |
| 2021-05-12 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-12-14 | 개시 | Jefferies | Buy |
| 2020-08-06 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-05 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-08-05 | 다운그레이드 | Ladenburg Thalmann | Neutral → Sell |
| 2020-07-16 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-08 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2020-06-29 | 재확인 | B. Riley FBR | Buy |
| 2020-06-29 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-05 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2020-05-28 | 재확인 | B. Riley FBR | Buy |
| 2020-05-12 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-30 | 재확인 | H.C. Wainwright | Buy |
| 2019-11-27 | 재개 | B. Riley FBR | Buy |
| 2019-08-14 | 재확인 | H.C. Wainwright | Buy |
| 2019-02-28 | 다운그레이드 | Piper Jaffray | Overweight → Underweight |
| 2018-12-18 | 개시 | Ladenburg Thalmann | Buy |
| 2018-12-11 | 개시 | Oppenheimer | Outperform |
| 2018-11-26 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2018-09-21 | 업그레이드 | JP Morgan | Underweight → Overweight |
| 2018-03-29 | 업그레이드 | Seaport Global Securities | Neutral → Buy |
모두보기
노바백스 주식(NVAX)의 최신 뉴스
Assessing Novavax (NVAX) Valuation After Recent Share Price Momentum And Partnership Shifts - Yahoo Finance
Amphastar Pharmaceuticals, Novavax, and Organon Shares Skyrocket, What You Need To Know - Finviz
Why institutional investors increase stakes in Novavax Inc. (NVV1) stockWeekly Market Outlook & Entry and Exit Point Strategies - mfd.ru
The Truth About Novavax Inc (NVAX): Comeback Story or Total Bag Fumble? - AD HOC NEWS
Novavax (NVAX) Rises As Market Takes a Dip: Key Facts - Yahoo Finance
Novavax (NVAX) Stock Price, News & Analysis - MarketBeat
Human Vaccine Adjuvants Market Forecast with Size and Share Analysis 2026 to 2035 - Insightace Analytic
Novavax, Inc. (NVAX) Investor Outlook: Exploring a Potential 48.15% Upside in the Biotechnology Arena - DirectorsTalk Interviews
Allianz Asset Management GmbH Acquires 872,987 Shares of Novavax, Inc. $NVAX - MarketBeat
(NVAX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
RSI Check: Is Novavax Inc a defensive stockMarket Rally & Reliable Price Breakout Signals - baoquankhu1.vn
Market Review: Is Novavax Inc a defensive stockProduct Launch & Verified Momentum Stock Watchlist - baoquankhu1.vn
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Novavax rises after a seven-day slide - MSN
Novavax, Inc. (NVAX) Stock Analysis: Assessing a 48% Potential Upside Amidst Market Challenges - DirectorsTalk Interviews
Why Novavax (NVAX) Dipped More Than Broader Market Today - Yahoo Finance
Pfizer Taps Novavax Matrix-M To Refresh Vaccine Growth Story - Yahoo Finance
Pfizer Reshapes Portfolio With Metsera Deal Novavax Pact And R&D Push - simplywall.st
Pfizer Q4 Earnings Preview: Analysts Expect Decline - Intellectia AI
Pfizer Likely To Report Lower Q4 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call - Benzinga
Earnings Update: Can Novavax Inc stock outperform in a bear marketJuly 2025 Sector Moves & Free Reliable Trade Execution Plans - baoquankhu1.vn
Novavax COVID-19 vaccine approved by the FDA - MSN
Weekly Earnings: Is Novavax Inc a turnaround storyGap Down & Accurate Technical Buy Alerts - baoquankhu1.vn
AI Stocks: Whats the beta of Novavax Inc stockPortfolio Value Summary & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
BofA Notes Positive Interest in Novavax, Inc. (NVAX) Technology Despite Timing Concerns for Licensed Assets - Finviz
Novavax (NASDAQ:NVAX) Lowered to Sell Rating by Wall Street Zen - MarketBeat
9 High Growth Small Cap Stocks That Are Profitable - Insider Monkey
Moderna Vs. Novavax: 2 Pandemic Vaccine PioneersWhich Offers Better Value Today? (MRNA) - Seeking Alpha
Pfizer Balances Vaccine Expansion And Drug Discounts With Novavax And TrumpRx - Yahoo Finance
This Beaten-Down Biotech Is Showing Signs of Life. Is It a Buy? - Finviz
This Beaten-Down Biotech Is Showing Signs of Life. Is It a Buy? - The Motley Fool
Pfizer Inks $530M Deal for Novavax Matrix-M Adjuvant Technology to Boost Vaccine Pipeline - Finviz
Here's Why Novavax (NVAX) Fell More Than Broader Market - Yahoo Finance
Why Is Pfizer Stock Rising Tuesday? - Sahm
Has Novavax cracked the code for survival in the vaccine arena? - PharmaVoice
Novavax, Inc. (NASDAQ:NVAX) Given Average Rating of "Hold" by Analysts - MarketBeat
Pfizer Reshapes Pipeline With Novavax Deal And ViiV Exit - simplywall.st
Responsive Playbooks and the NVAX Inflection - Stock Traders Daily
Novavax rises after licensing deal with Pfizer - MSN
Novavax, Inc. (NVAX) Stock Analysis: Exploring a 33.84% Potential Upside in the Biotechnology Sector - DirectorsTalk Interviews
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It - sharewise.com
What's Driving the Market Sentiment Around Novavax Inc? - Benzinga
MRNA vs NVAX: Which vaccine stock is Wall Street more bullish on right now? - MSN
Novavax (NASDAQ:NVAX) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Assessing Novavax (NVAX) Valuation After Pfizer Licensing Deal For Matrix M Adjuvant - Sahm
Decliners Report: Is Novavax Inc a play on infrastructure spendingRate Hike & Safe Entry Momentum Tips - baoquankhu1.vn
Will Licensing Novavax’s Matrix-M Adjuvant Reshape Pfizer’s (PFE) Vaccine Platform Strategy? - Yahoo Finance
Reassessing Novavax (NVAX) After Recent Share Price Rebound And Valuation Signals - Yahoo Finance
Novavax grants license for use of Matrix-M adjuvant to Pfizer - MSN
Novavax (NVAX) Stock Dips While Market Gains: Key Facts - Yahoo Finance
Novavax Pfizer Licensing Deal Puts Matrix M And Valuation In Focus - Sahm
노바백스 (NVAX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.12%
0.87%
자본화:
|
볼륨(24시간):